anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cocaine use disorder (CUD) is a chronic disorder associated with numerous relapses and periods of abstinence.

Studies in CUD suggest that \~ 60 to 75% of abstinent addicts relapse over twelve months Documenting specific neurochemical abnormalities that lead to relapse in individuals with CUD has the potential to accelerate the development of medications to prevent relapse. Basic investigations postulate an imbalance between brain stress and anti-stress/resilience systems as the underlying mechanism that drives negative reinforcement, craving, and relapse in addiction. Nociceptin (N/OFQ), which binds to the nociceptive opioid peptide receptors (NOP) is a critical component of the brain's anti-stress system. N/OFQ counteracts the functional effects of the primary stress-promoting neuropeptide corticotrophin releasing factor (CRF) in the brain to exert its anti-stress effects. Studies have also shown that acute increases in CRF and stress are countered by increased NOP receptor expression (\~ 10% ) in brain regions that regulate stress such as bed nucleus of the stria terminalis. PET studies with the NOP radiotracer \[11C\]NOP-1A show increased binding to NOP in CUD compared to HC. PET studies also show NOP receptors to upregulate (\~ 15%) in response to an acute intravenous hydrocortisone challenge (1 mg/Kg). NOP upregulation may represent an adaptive mechanism in the brain to counteract stress-induced increases in cortisol and CRF. Here, we postulate a failure in this adaptive mechanism as a reason that leads to relapse in CUD. CUD subjects and HC will be studied with \[11C\]NOP-1A before and after an intravenous hydrocortisone challenge (aim 1). Hydrocortisone is used as a challenge because it increases cortisol and CRF in brain regions that regulate stress. We hypothesize that hydrocortisone-induced increases in \[11C\]NOP-1A binding (DELTA VT) will be smaller in CUD relative to HC, and this will be associated with less time to relapse in a 12-week follow up.
Controlled diabetes (HbA1c level \<7%). This group will study the natural course of RANKL levels in balanced diabetic patients.
1. A liposomatic vaccine composition comprising an antige or an antige composition, an immunologically active saponin fraction and a sterol, characterized in that ratio of saponin : sterol is from 1:1 to 1:100 (w/w). 2. A vaccine composition according to claim 1 wherein the ratio of saponin : sterol is from 1:1 to 1:5. 3. A vaccine composition according to claim 1 wherein the ratio of saponin : sterol is 1:2 (w/w). 4. A vaccine composition according to any claims 1 to 3, wherein the immunologically active saponin fraction is QS21. 5. A vaccine composition according to any claims 1 to 3, wherein the sterol is cholesterol. 6. A vaccine composition according to any claims 1 to5, which further contains 3D-MPL. 7. A vaccine composition according to any claims 1 to 6, further comprising a carrier, which is aluminum salt or aluminum hydroxide, or emulsion of type "oil in water". 8. A vaccine composition according to any claims 1 to 7, characterized in that an antigen or antigenic composition derived from any of Human Immunodeficiency Virus, Feline Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium or Toxoplasma. 9. A vaccine according to any of claims 1 to 7, characterized in that an antigen or an antigen composition are derived from a tumor. 10. A vaccine according to any of claims 1 to 9, characterized in that is used in medicine. 11. Use of liposomatic composition comprising immunologically active saropin fraction and a sterol, characterized in that ratio of saponin : sterol is from 1:1 to 1:100 (w/w) for the manufacture of a vaccine for the prophylactic and/or for the immunotherapeutic treatment of viral, bacterial, parasitic infections or cancer. 12. A method of treating a mammal suffering from or susceptible to a pathogenic infection, characterized in that comprising the administration of a safe and effective amount of a composition according to any of claims 1 to 8. 13. A method of treating a mammal suffering from cancer, characterized in that comprising the administration of a safe and effective amount of a composition according to claim 9. 14. A process for making a vaccine composition according to any claims 1 to 9, characterized in that comprising admixing an immunologically active saponin fraction and sterol, in particular, cholesterol with an antigen or antigenic composition.
This group included COVID19 patients with acute respiratory distress syndrome. Patients were put under prone position while their pulmonary function was measured using EIT before and after proning.
The study consists of two groups of children to be recruited in different centers in India. One group will receive the HRV vaccine and one group will receive the placebo. The vaccine or placebo will be administered starting at 8-12 weeks of age, according to a two dose schedule (0, 1 months schedule). The study will consist of three visits. A 8-day (Day 0 - 7) follow-up period will be observed for general symptoms solicited in the study. A 31-day (Day 0 - 30) follow-up will be observed for other unsolicited symptoms. Serious adverse events (SAEs) will be followed-up throughout the study. A stool sample will be collected from the child at any point during the study if he/ she develops any GE.
BELRAPZO contains no antimicrobial preservative. The admixture should be prepared as close as possible to the time of patient administration.

If diluted with 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, the final admixture is stable for 24 hours when stored refrigerated (2°C to 8°C or 36°F to 46°F) or for 3 hours when stored at room temperature (15°C to 30°C or 59°F to 86°F) and room light. Administration of diluted BELRAPZO must be completed within this period of time.

BELRAPZO (bendamustine hydrochloride injection) is supplied in a multiple-dose vial. Retain the partially used vial in original package to protect from light and store refrigerated (2°C to 8°C or 36°F to 46°F) if additional dose withdrawal from the same vial is intended.
OBJECTIVE: Deep-learning techniques, particularly the Transformer model, have shown great potential in enhancing the prediction performance of longitudinal health records. Previous methods focused on fixed-time risk prediction, however, time-to-event prediction is often more appropriate for clinical scenarios. Here, we present STRAFE, a generalizable survival analysis Transformer-based architecture for electronic health records.
MATERIALS AND METHODS: The input for STRAFE is a sequence of visits with SNOMED-CT codes in OMOP-CDM format. A Transformer-based architecture was developed to calculate probabilities of the occurrence of the event in each of 48 months. Performance was evaluated using a real-world claims dataset of over 130 000 individuals with stage 3 chronic kidney disease (CKD).
RESULTS: STRAFE showed improved mean absolute error (MAE) compared to other time-to-event algorithms in predicting the time to deterioration to stage 5 CKD. Additionally, STRAFE showed an improved area under the receiver operating curve compared to binary outcome algorithms. We show that STRAFE predictions can improve the positive predictive value of high-risk patients by 3-fold. Finally, we suggest a novel visualization approach to predictions on a per-patient basis.
DISCUSSION: Time-to-event predictions are the most appropriate approach for clinical predictions. Our deep-learning algorithm outperformed not only other time-to-event prediction algorithms but also fixed-time algorithms, possibly due to its ability to train on censored data. We demonstrated possible clinical usage by identifying the highest-risk patients.
CONCLUSIONS: The ability to accurately identify patients at high risk and prioritize their needs can result in improved health outcomes, reduced costs, and more efficient use of resources.
In the control group, patients will receive an intravenous administration (1-10 g of TxA) at the induction of anesthesia as a bolus and/or continuous infusion (i.e., before CPB). In addition, patients will receive an intravenous administration (50 mL of saline placebo) after heparin reversal.
Intervertebral disc (IVD) degeneration is an important clinical problem that often contributes to low back pain and degenerative disc diseases. Degeneration of the IVD induces anulus tears and fissures, which can cause severe discogenic low back pain. Because the IVD has little potential to self-regenerate, treatment of degenerative disc disease is one of the most challenging clinical problems facing the spine surgeon. Platelet-rich plasma (PRP) is a fraction of plasma that contains platelets and multiple growth factors concentrated at high level. Because activated platelets have the potential to release growth factors, PRP has been clinically used to accelerate wound healing and tissue regeneration in orthopedic and oral surgery. The soluble releasate isolated from PRP has recently been demonstrated to influence the metabolism of intervertebral discs in vitro. Furthermore, an intradiscal injection of autologous PRP has been shown to induce restoration of structural changes in the rabbit annular injection model in vivo. This clinical trial aims to investigate the safety and efficacy of intradiscal PRP injection in patients with discogenic low back pain. The pre- and post-interventional imaging and clinical outcomes will be compared.
PROBLEM TO BE SOLVED: To obtain an aldose reductase inhibitor comprising an extract of Centella asiatica with a lower alcohol as an active ingredient, capable of readily inhibiting an aldose reductase, useful for preventing and improving symptom following diabetic peripheral nerve disorder and diabetic cataract. SOLUTION: This inhibitor comprises an extract (preferably at least petuletin, kaempferol-3-O-β-D-glucuro-pyranoside, 2,5-dihydroxy-benzoic acid, etc.), of Centella asiatica with a lower alcohol, preferably an extract with ethyl acetate as an active ingredient. The extract organosiloxane Centella asiatica with the lower alcohol is obtained by extraction with methanol. The extraction is carried out by immersing Centella asiatica in an extracting solvent, oozing the extract at 75-85 deg.C for 2-4 hours and removing the residue. The mixing ratio (volume) of Centella asiatica and the lower alcohol is 1:10 in the whole extraction process. In the dose of the extract of Centella asiatica with the lower alcohol, preferably 0.5 g of the extract per time is administered once to four times daily in the case of using an ethyl acetate soluble fraction.
<P>PROBLEM TO BE SOLVED: To regulate TH1 type/TH2 type cytokine generation by ribavirin and ribavirin analog in an activated T lymph cell.  <P>SOLUTION: In this invention, ribavirin is administered to a patient within the range of dosage effective for the regulation of lymphokine in an activated T cell. Especially, ribavirin is used for the restraint of Th2 mediated T cell response and for the promotion of Th1 mediated T cell response. At least one ribavirin analog is administered to a patient within the range of dosage effective for the regulation of the generation of lymphokine in an activated T cell. The ribavirin analog can be used for the restraint or promotion of Th1 or Th2 mediated T cell response.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Comparative evidence for the effects of bariatric metabolic surgery (BMS) and glucagon-like peptide-1 receptor agonists (GLP-1RA) on cardiovascular outcomes is limited. Here, in an observational, retrospective cohort study, we compared the incidence of congestive heart failure (CHF) in adults living with obesity and diabetes without history of CHF (primary CHF) treated with BMS versus GLP-1RA. The population cohort comprised members of Clalit Health Services with no prior history of ischemic heart disease, ischemic stroke or CHF. During the time period of 2008-2021, patients who underwent their first BMS were matched 1:1 with patients who initiated treatment with GLP-1RA, based on clinical characteristics. The study included 2,205 matched pairs of patients (64.5% female), followed for a median of 6.6 years and up to 12 years. Primary incidence of CHF occurred in 26 (1.2%) patients treated with BMS and in 90 patients treated with GLP-1RA (4.1%) (adjusted hazard ratio 0.43, 95% confidence interval 0.27-0.68). Further adjustment for weight reduction did not significantly diminish this association (hazard ratio adjusted for weight reduction 0.48, 95% confidence interval 0.28-0.82), indicating that the differential effect was not mediated through the relative advantage of BMS in maximal weight reduction. In this study, BMS was associated with a stronger reduction in primary incidence of CHF compared with treatment with GLP-1RA. With the increasing use of highly potent next-generation GLP-1RAs, further comparative long-term studies are warranted.
BACKGROUND & AIMS: GLIM definition of malnutrition is recognised all over the world and, when is referring to cancer, it specifies that weight or muscle loss are associated with an inflammatory status. However, the real-world practice shows that GLIM definition cannot encompass all the wide and heterogenous clinical presentations of cancer patients with malnutrition, which involves many other drivers beyond inflammation. Moreover, placing an excessive emphasis on the inflammation can overshadow, in the clinical practice, the role of the nutritional support in malnourished cancer patients. The aim of this paper is not to criticize the rationale of the GLIM definition of cancer cachexia, but to show the complexity and heterogeneity of malnutrition of cancer patients and reasons why nutritional support should deserve such a better consideration among the oncologists.
METHODS: Literature pertinent to pathophysiology of malnutrition of cancer patients is scrutinised and reasons for the frequent underuse of nutritional support are critically analysed.
RESULTS: The appraisal of the literature shows that there are various pathophysiological patterns of malnutrition among cancer patients and inflammatory markers are not universally present in weight-losing cancer patients. Inflammation alone does not account for weight loss in all cancer patients and factors other than inflammation can drive hypophagia and weight loss, and hypophagia appears to be a primary catalyst for weight loss. Furthermore, malnutrition may be the consequence of the presence of several Nutrition Impact Symptoms or of the oncologic therapy. The nutritional support may fail to show benefits in malnourished cancer patients because the golden standard to validate a therapy relies on RCT, but it is ethically impossible to have an unfed control group of malnourished patients. Furthermore, nutritional interventions often fell short of the optimal standards, adherence to treatment plans was often poor, nutritional support was mainly reserved for very advanced patients and the primary endpoints of the studies on nutritional support were sometimes unrealistic.
CONCLUSION: There is a gap between the suggestion of the guidelines which advocate the use of nutritional support to improve the compliance of patients facing intensive oncologic treatments or to prevent an early demise when patients enter a chronic phase of slow nutritional deterioration, and the poor use of nutrition in the real-world practice. This requires a higher level of awareness of the oncologists concerning the reasons for the lacking evidence of efficacy of the nutritional support and an understanding of its potential contribute to improve the outcome of the patients. Finally, this paper calls for a change of the oncologist's approach to the cancer patient, from only focusing on the cure of the tumour to taking care of the patient as a whole.
The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes methods of making and using the surface-layer protein coated microspheres of the invention for administering therapeutic agents to a subject in need thereof. The invention also includes pharmaceutical dosage units that include the surface-layer protein coated microspheres of the invention. The invention further includes various labeled defensins for use in the study of the properties and actions of defensins, and further includes the use of defensins, particularly HD5.alpha. in the treatment of inflammatory conditions of the bowel, such as Crohn's disease.
Bexagliflozin can cause intravascular volume contraction which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine [see Adverse Reactions ( 6.1)] . There have been postmarketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors. Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2) [see Use in Specific Populations ( 8.6)] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. Before initiating bexagliflozin tablets in patients with one or more of these characteristics, assess volume status and renal function [see Dosage and Administration ( 2.1)] . In patients with volume depletion, correct this condition before initiating bexagliflozin tablets. Monitor for signs and symptoms of volume depletion, and renal function after initiating therapy.
Increasing evidence has suggested that ubiquitin-specific protease 10 (USP10), a deubiquitinating enzyme, plays an essential role in targeted protein degradation and participates in cancer progression. However, the relationship between USP10 and pancreatic ductal adenocarcinoma (PDAC) is poorly understood. Here, we developed a USP-targeting siRNA library, combining a loss-of-function experimental screen in patient-derived PDAC cells. This approach identified USP10 as a master regulator of PDAC cell migration. High USP10 expression levels were observed in PDAC patient tissues, which were associated with poor prognosis. Furthermore, knockdown of USP10 expression inhibited PDAC cell proliferation and migration in vivo and in vitro. Mechanistically, USP10 increased FOXC1 protein stability via deubiquitination. The phosphorylation of FOXC1 at S272A was dependent on USP10-mediated deubiquitination of FOXC1. Additionally, USP10 promoted FOXC1 protein localization in the nucleus. Interestingly, FOXC1 could increase USP10 mRNA expression levels by transcriptional activation. Our data suggest that a positive feedback loop exists between USP10 and FOXC1 that can activate WNT signaling, thus facilitating PDAC malignant progression. Therefore, USP10 represents an exciting therapeutic target that could support new strategies for treating PDAC.
Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident colorectal cancers as all deaths that occur among both screened and control subjects during the trial.
Individuals with Alcohol Use Disorder will be recruited from Lodging Plus treatment program (Fairview Riverside Hospital, Minneapolis, MN). All patients will have between 2-3 weeks of abstinence from alcohol use. We will collect brain imaging data, this is an observational study.
A non-transitory computer-readable storage medium storing a set of instructions executable by a processor, the set of instructions, when executed by the processor, causing the processor to perform operations including receiving a self-care assessment from a patient having a medical condition. The self-care assessment assesses the patient's level of ability for each of a plurality of determinants. The operations also include assigning a weight to each of the plurality of determinants. The operations also include creating an ordered list including the plurality of determinants. The determinants are ordered based on the corresponding weights. The operations also include determining a plurality of behavior-specific contributions. Each of the behavior-specific contributions corresponds to one of the determinants and to one of a plurality of self-care behaviors relevant to the medical condition.
Patients who have undergone stoma surgery will be divided into two groups as control and intervention by simple randomization. Patients assigned to the control group will receive standard stoma care training applied by the clinic. Patients will be met before surgery and necessary information will be obtained. A total of 5 interviews will be conducted with patients in both groups.
Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
Patients with supratentorial ependymoma (Grade II without GTR1 or ST Grade III) or any infratentorial ependymoma (Grade II or III) who have undergone gross or near total resection or achieved CR either after first or second resection or after post-operative induction chemotherapy are randomized to undergo conformal radiotherapy over 6-7 weeks and then undergo observation. Patients without GTR or NTR at enrollment require induction chemotherapy (see Arm I) and possibly second surgery before randomization.
PURPOSE:To allow a child or an aged person to easily operate the hospital guiding device and execute necessary procedure by outputting question items stored in a storage means from an image/voice output means in accordance with the patient's operation of a key entry means. CONSTITUTION:When the power supply of the guiding device is turned on, guidance for procedure to be executed by a patient write in a program ROM 4a at the time of first medical examination is outputted from a display 2 and a speaker 7 as voice data and image data. While listening the voice from the speaker 7 and observing the displayed contents of the display 2, the patient in the first medical examination operates a keyboard 3 and depresses keys relating to the first medical examination with a touch pen 9. Thereby, the procedure for the first medical examination stored in the ROM 4a is read out and outputted from the display 2 and the speaker 7. When the patient responds to the guidance through the keyboard 3, various procedures necessary for the first medical examination can be executed. Then, the department to be examined, its road guide, waiting time information, etc., are displayed and outputted as voice.
Patients will be placed in supine lithotomy position with 60-90° oblique on the affected side upward. A pressure measuring ureteral access sheath (UAS) (11-14Fr) is inserted into the proximal ureter along the guidewire without fluoroscopic guidance. The pressure sensory and suctioning channels are connected to the irrigation and suctioning platform.